Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-1018 in Advanced Solid Tumors
NCT04928612Phase 1Recruiting
- Sponsor
- Coherent Biopharma
- Start
- Nov 2021
- Primary completion
- Oct 2024
- Modality
- Antibody-Drug Conjugates (ADCs), Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CBP-1018 in solid tumor (advanced stage), metastatic castration-resistant prostate cancer (mCRPC), renal cell carcinoma (RCC) and 1 more, sponsored by Coherent Biopharma. Primary endpoints: Incidence and severity of Adverse Events (AEs) at 12 months, Maximum Tolerated Dose at 12 months and 2 more. Started Nov 2021; status: recruiting.
02
Drugs
CBP-1018
03
Conditions
solid tumor (advanced stage)metastatic castration-resistant prostate cancer (mCRPC)renal cell carcinoma (RCC)lung cancer
Beyond the preview
Go deeper on NCT04928612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928612.